Bendamustine is a novel cytostatic agent, with activity in nonHodgkin's lymphomas including B-chronic lymphocytic leukemia (B-CLL). The knowledge about its mode of action, however, is still limited. Here, we investigated the in vitro ability of bendamustine to induce apoptosis on freshly isolated peripheral lymphocytes in B-CLL and analyze the potential underlying mechanisms of action for inducing apoptosis. In CLL cells taken from 37 previously treated and untreated CLL patients, we investigated the influence of bendamustine alone, and in combination with fludarabine, on the induction of apoptosis and changes of Bcl-2 and Bax expression on mRNA and protein level using the RNase protection assay or flow cytometry, respectively. Apoptotic cells were determined with flow cytometry using the fluorescent DNA-binding agent 7-ADD. Using bendamustine alone in concentrations from 1 g/ml to 50 g/ml, a dose-and time-dependent manner of cytotoxicity from 30.4% to 94.8% after 48 h could be observed. The LD50 for untreated and pretreated CLL cells was 7.3 or 4.4 g/ml, respectively. The median apoptotic rate was similar in both groups. The combination of bendamustine with fludarabine led to a highly synergistic effect in inducing apoptosis, which was 150% higher than expected for bendamustine plus fludarabine. The level of the initial Bcl-2 and Bax protein and the m-RNA expression remained unchanged during the incubation with bendamustine. In conclusion, this study demonstrates for the first time the in vitro efficacy of bendamustine in inducing apoptosis in B-CLL cells alone and in combination with fludarabine.
Introduction
B chronic lymphocytic leukemia (B-CLL) is the most common type of leukemia in the western world. 1 This disorder is characterized by the monoclonal accumulation of CD5 + mantle zone-based resting B cells. 2 More than 99% of these cells seem to be at the G 0 phase of the cell cycle. 3 It has been suggested that the prolonged excess of B cells rather is a result of decreased apoptosis and dysregulation of cell cycle control than an increase of proliferation. [4] [5] [6] [7] In normal tissues, a homeostasis is maintained by the balance between proliferation and apoptosis, which is controlled by a large variety of different genes regulating this process. One of these gene families, which is of interest concerning CLL, is the Bcl-2 family. 8 Here overexpression of Bcl-2 has been previously reported for B-CLL cells. 9, 10 Additionally, a relatively decreased expression of Bax in patients with CLL, as a proapoptotic member of the Bcl-2 family, which forms heterodimers with Bcl-2, is associated with a poor prognosis. 11, 12 It is yet unknown how the expression of the mem-bers of the Bcl-2 family are regulated and whether they can influence the drug sensitivity of B-CLL cells in vitro. 13, 14 Caspase activation, following different stimuli, plays a key role in the apoptotic pathways by a specific cleavage of important cellular essential enzymes. 15, 16 This activation mechanism seems to be under the control of dimerizing Bcl-2 family members. [17] [18] [19] In recent years, fludarabine and 2-chlorodeoxyadenosine, adenine nuceoside analogs, have been shown to be one of the most active single agents in CLL. [20] [21] [22] They act on proliferating as well as on resting B cells via induction of apoptosis. The high remission rates, including clinical complete remissions, has opened new possibilities in treatment strategies of CLL. In comparison with most other forms of acute and chronic leukemias, no curative therapy option has been realized so far for B-CLL. Therefore, a major concern in the treatment of CLL to overcome the development of resistance and to prolong life, is to find new therapy options including new mechanisms of action, apart from existing drugs, such as alkylators or purine analogs.
In this context, bendamustine, a novel agent with activity in non-Hodgkin's lymphomas (NHL), including CLL and some other malignancies, might be of major interest. [23] [24] [25] [26] [27] [28] [29] Bendamustine belongs to the group of bifunctional alkylating agents. The nitrogen mustard group in position 5 is linked to a benzimidazol nucleus, showing a methyl-group in position 1 and a butanoic acid residue in position 2 ( Figure 1 ). By adding the benzimidazol nucleus and the butanoic acid residue to the nitrogen mustard group, bendamustine hydrochloride probably combines the features of alkylating agents with those of purine-and aminoacid analogs. Its alkylating toxicity is based on cross linking of DNA single and double strand breaks. In contrast to other alkylating agents, it induced more long-lasting DNA double strand breaks, indicating different interactions with DNA. 30 This may explain the lack of complete cross resistance between bendamustine and other alkylating agents, such as cyclophosphamide or chlorambucil. 30 As the knowledge about its mode of action is still limited, we investigated the in vitro ability of bendamustine to induce apoptosis on freshly isolated peripheral lymphocytes in B-CLL
Figure 1
Chemical structure of bendamustine.
and analyzed the potential underlying mechanisms of action for inducing apoptosis. In detail, we investigated whether this drug acts by inducing apoptosis or by necrosis inducing cytotoxicity, and studied the possible alterations in the expression of the apoptotic relevant genes Bcl-2 and Bax. As the combination of bendamustine and fludarabine had been tested in first clinical trials, we studied the efficiency of this combination concerning its assumed synergistic interaction in induction of apoptosis in vitro.
Materials and methods

Patients and cell separation
Peripheral blood samples from 37 (17 treated and 20 untreated) patients with high leukemic B-CLL were obtained after informed consent. The diagnosis of B-CLL was confirmed by clinical, morphological and immunological criteria. Fifteen patients had Binet stage A, six stage B, 16 stage C diseases (see Table 1 ). Pretreated patients had been without treatment for at least 1 month. Pretreated patients received chlorambucil ± prednisone and/or fludarabine therapy. Only three of them received further cytotoxic drugs, such as vincristine or 2-CDA. Peripheral blood mononuclear cells (PBMC) were isolated using density Ficoll-Hypaque gradient centrifugation (Seromed, Berlin, Germany). Peripheral monocytes were depleted by plastic adhesion. Cells were resuspended in RPMI 1640 medium (GIBCO-BRL, Paisley, UK) supplemented with 1% penicillin/streptomycin, 1% glutamate and 10% heatinactivated FCS and cultured at 37°C in a humidified atmosphere containing 5% carbon dioxide.
Induction of apoptosis
In order to analyze the induction of apoptosis in CLL-patients (n = 31) or healthy donors (n = 4), 5 ml of 1 × 10 6 /ml PBMC were exposed in vitro to either medium or varying concentrations of bendamustine (Ribosepharm, Munich, Germany) (1 g/ml, 2 g/ml, 4 g/ml, 5 g/ml, 10 g/ml, 20 g/ml, 30 g/ml, 40 g/ml and 50 g/ml) and fludarabine (Medac Schering, Munich, Germany) (0.35 g/ml, 0.7 g/ml, 3.5 g/ml, 7 g/ml, 10 g/ml and 14 g/ml). Additionally the following drug combinations were evaluated over a period of 72 h: 1 g/ml bendamustine/0.35 g/ml fludarabine, 2 g/ml bendamustine/0.7 g/ml fludarabine and 10 g/ml bendamustine/3.5 g/ml fludarabine.
Bendamustine was dissolved in aqua bidestillata in a con- Leukemia centration of 4 mg/ml and afterwards frozen at −20°C to prevent rapid and quantitative hydrolysis. Immediately before incubation, bendamustine was diluted with 0.9% NaCl to the appropriate concentrations. Fludarabine was dissolved in 0.9% NaCl to a concentration of 7 mg/ml and frozen at −20°C. Before the incubation in cell culture, fludarabine was further diluted with 0.9% NaCl to the final concentration of 0.7 g/ml in the cell culture suspension. Pre-experiments showed no different outcome in the amount of apoptosis in CLL cells whether using the biologically active dephosphorylated form of fludarabine (9-␤-D-arabinofuranosyl-2-fluoroadenine; Sigma, Munich, Germany) or the customary cytotoxic drug fludarabine monophosphate (data not shown).
Measurement of apoptosis
The quantification of apoptosis was measured 24 h, 48 h and 72 h after addition of cytotoxic drugs with the DNA dye 7 amino-actinomycin D (7-AAD, Sigma). The measurement of apoptotic cells with the fluorescent DNA-binding agent 7-AAD is based on diffusion through the altered membranes in apoptotic cells and the subsequent intercalation between cytosin and guanine. 31 This method was described as a fast and valid method to detect and quantify apoptosis in different cell types. [31] [32] [33] In detail, one million cells obtained from the cell culture were washed in PBS and were resuspended in 100 l PBS and 20 l 5 mg/ml 7-AAD. Cells were stained for 20 min at 4°C, protected from light. The number of apoptotic cells was determined by the fluorescence intensity on a logarithmic scale (Figure 2 ) on FACS Calibur flow cytometer (Becton Dickinson, Heidelberg, Germany) using Lysis-II software. The data were analyzed with the Paint-a-Gate Pro software (Becton Dickinson). At least 10 000 events of each sample were analyzed. Cell debris and necrotic cells could easily be differentiated from apoptotic cells and were excluded from analysis by setting a threshold. The percentage of apoptotic cells of all evaluated cells was calculated in the control population, incubated in culture medium, as well as for all other drug concentrations and combinations. For the determination of the LD50 and LD40 the amount of the drugspecific apoptosis was calculated as described by Friesen et al. 34 This process excludes the influence of spontaneous apoptosis in CLL cells cultured in vitro.
(Drug induced apoptosis − spontaneous apoptosis) 100 − spontaneous apoptosis × 100. 
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Additionally we evaluate the interaction of bendamustine and fludarabine by isobologram analysis and determination of the combination index (CI; CI Ͻ 1 = synergism, CI Ͼ 1 = antagonism), as previously described by Chou et al, 35, 36 using Calcusyn software (Biosoft, Cambridge, UK).
FACS analysis and quantitation of Bcl-2 and Bax protein expression
The evaluation of the Bcl-2 and Bax protein expression in samples from B-CLL patients (n = 15) was performed as described previously 37 and modified in the following steps: 1 × 10 6 cells were centrifuged and washed in PBS supplemented with 1% BSA. The cells were fixed in 100 l reagent A (Fix and Perm Kit, Grub, Kaumberg, Austria) for 15 min at room temperature. Cells were then washed once in PBS/BSA 1% and permeabilized in 100 l reagent B (Fix and Perm Kit). The indirect staining for Bcl-2 and Bax was performed by the incubation with 5 l of 100 g/ml anti-Bcl-2 monoclonal antibody (MoAb) (hamster anti-human Bcl-2, Pharmingen, San Diego, CA, USA) and 2 l of 1 g/l anti-Bax MoAb (mouse anti-human Bax, Immunotech, Marseille, France) or for the IgG-isotype control with 1 l of 500 g/ml purified Armenian hamster IgG and 20 l of 50 g/ml mouse IgG (Pharmingen), for 20 min at room temperature in darkness. After further washing with PBS/BSA 1% the cells were subsequently incubated with 2 l of 1 mg/ml goat anti-Armenian hamster IgG-FITC (Dianova, Hamburg, Germany) and 10 l of 500 g/ml rabbit anti mouse IgG-PE (DAKO, Carpinteria, CA, USA).
After washing with PBS, the mean fluorescent intensity (MFI) of Bcl-2 and Bax expression was measured on a logarithmic scale on FACS Calibur flow cytometer (Becton Dickinson) by subtracting the background fluorescence of the relevant IgG-isotype control.
RNase protection assay
In order to detect and quantify the expression of Bcl-2, Bax and the housekeeping gene L32 and GAPDH total RNA of 1 × 10 7 cells from four different patients were cultured in the presence of 2 g/ml bendamustine. RNA was isolated after 2, 4, 8, 24 and 48 h of incubation using the TRIZOL RNA extraction method (GIBCO/BRL, New York, NY, USA). 10 g of total target RNA was hybridized against 32 P-labeled anti-sense RNA probe generated by in vitro transcription from a DNA template set according to the instruction manual (Pharmingen). Following RNase treatment, to degrade singlestranded RNA and labeled RNA probe, the hybridization product was resolved by denaturing PAGE (7.5% polyacrylamide; 7 M urea; in 0.5 × TBE; 2.5 h, 70 W) and visualized by autoradiography. Radioactivity for each probe and sample was quantified by phosphorimaging.
Western blotting analysis of PARP
In order to confirm FACS data concerning the differentiation between apoptosis and necrosis, we performed poly (ADPribose) polymerase (PARP) Western blotting. B-CLL cell pellets were resuspended in Laemmli buffer (500 mM Tris HCl, 100 mM DTT, 2% SDS, 0.1% bromphenol blue, 10% glycerol, pH 6.8), boiled and resolved by 8% SDS-PAGE. After the protein transfer to immobilon-polyvinylidene difluoride (PDVF) membranes (Millipore, Bedford, MA, USA) by tank blotting, the proteins were visualized by amido black staining. The membranes were then saturated in PBS containing 0.05% Tween 20 and 5% non fat milk for 1 h at 37°C, and subsequently treated with primary antibody (Stratagene, La Jolla, CA, USA) to detect the intact PARP molecule, as well as the 89-kDa fragment characteristic for apoptotic cells. Immunoreactive proteins were detected by incubation with peroxidase-conjugated anti-mouse IgG (Amersham, Freiburg, Germany) and enhanced chemiluminescence (ECL, Amersham).
Statistical analysis
Results are expressed as group medians and the corresponding interquartile range. For the statistical evaluation of differences in the median apoptotic rate among pretreated and untreated groups, for cells cultured either in control medium or under 2 g/ml bendamustine, we performed Wilcoxon rank sum test. For the statistical differentiation between pretreated or untreated CLL cells grown in control medium or under the incubation with 2 g/ml bendamustine, we performed Wilcoxon signed rank test. The LD50 for untreated and pretreated CLL patients and healthy donors was calculated by linear regression analysis (logarithm of doses vs viability). Since in these results the confidence intervals of all groups showed no overlapping, these groups revealed significant differences (analogous to the Student's t-test). To analyze the differences between the synergistic action of the combination of bendamustine and fludarabine in comparison to the expected additive rate of the single agents, we performed Wilcoxon signed rank test. The Bcl-2 and Bax protein expression, under the incubation with bendamustine or control medium, was analyzed with the non-parametric Page test.
In all test P values were considered significant when р0.05.
Results
Cytotoxicity of bendamustine towards B-CLL and normal mononuclear cells
The apoptotic rate was quantitated by flow cytometry analysis over a period of 72 h with the DNA dye 7-AAD. [31] [32] [33] The apoptotic rates of B-CLL cells at each time and concentration were calculated as described above.
First, the dose-response and time kinetics of bendamustine on peripheral CLL cells from highly leukemic patients were studied. B-CLL cells were cultured in the presence of different concentrations of bendamustine (1 g/ml, n = 23; 2 g/ml, n = 26; 5 g/ml, n = 24; 10 g/ml, n = 26; 30 g/ml, n = 24; 50 g/ml, n= 8), and apoptotic rate was measured after 24 h, 48 h and 72 h. Serving as a negative control, cells were incubated in culture medium alone. Bendamustine-induced apoptosis in B-CLL cells in a dose-and time-dependent manner. The resulting median of apoptosis ranged in the control population from 12.6% (8.3-17.1%), 17.8% (11.8-22 .7%) and 13.1% (7.9-16.9%) after 24 h, 48 h and 72 h. Equal amounts of spontaneous apoptotic CLL cells cultured in vitro were observed in several other studies. [38] [39] [40] [41] [42] For CLL cells incubated with various concentrations of bendamustine the apoptotic rate ranged between 14.5% (1 g/ml) and 80.9% (50 g/ml) after 24 h and from 30.8% to 100% after 72 h (Figure 3 ).
Only six of 26 patients showed no sensitivity towards the CLL cells were incubated with various concentrations of bendamustine (control, n = 26; 1 g/ml, n = 23; 2 g/ml, n= 26; 5 g/ml, n = 24; 10 g/ml, n = 26; 30 g/ml, n = 24; 50 g/ml, n = 8) and apoptotic rate was measured after 24 h, 48 h and 72 h. The resulting median of apoptosis ranged in the control population from 12.6% (8.3-17.1%), 17.8% (11.8-22.7%) and 13.1% (7.9-16.9%) after 24 h, 48 h and 72 h. For CLL cells incubated with bendamustine the apoptotic rate ranged between14.5% (1 g/ml) to 80.9% (50 g/ml) after 24 h and from 30.8% to 100% after 72 h. bendamustine incubation after 48 h (determined as an apoptotic rate of less than 5% in the presence of 2 g/ml bendamustine after 48 h of incubation in comparison to the related control experiment). Even in these cells apoptosis could be induced up to a rate of nearly 80-90% by using higher concentrations (data not shown).
To differentiate the in vitro efficiency of bendamustine according to the pretreatment status we assessed the cytotoxicity in relation to the preceding treatment. CLL-cells (n = 26) from untreated (n = 15) and pretreated patients (n = 11) were exposed to 2 g/ml bendamustine. The median range of apoptosis after 24 to 72 h was calculated. As Figure 4a -c shows, B-CLL cells showed variations in their spontaneous apoptotic rate (control) and in their drug sensitivity to bendamustine. Nevertheless, there was no significant difference in the apoptotic rate in B-CLL cells from untreated and pretreated patients in the control medium, as well as in CLL cells incubated with 2 g/ml bendamustine after 24, 48 and 72 h. However, in all cases a significant increase in the amount of apoptotic cells in bendamustine-treated cells in comparison with the control group could be demonstrated. These results could also be confirmed for other concentrations of bendamustine (data not shown).
Additionally, the LD50 for treated and untreated patients were calculated after the exposure to varying concentrations of bendamustine over a period of 48 h. We calculated here the drug-specific apoptotic rate to exclude the influence of the spontaneous apoptosis of CLL cells which ever occurs when these cells were cultured ex vivo. The LD50 for treated patients (4.3 g/ml; 95% confidence interval (CI) 3.8-4.9 g/ml) was significantly lower compared with untreated patients (7.4 g/ml; 95% CI 6.5-8.3 g/ml). These results suggest that the in vitro sensitivity of B-CLL cells to bendamustine is not influenced by prior treatment. This fact confirmed clinical data showing a high response rate for bendamustine therapy in refractory or relapsed CLL patients. 23, 24 To evaluate the specificity of bendamustine against B-CLL cells, we incubated mononuclear cells from four healthy donors to different concentrations (2 g/ml, 4 g/ml, 20 g/ml
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Figure 4
CLL cells from pretreated (pre) í and untreated patients showed no differential sensitivity towards in vitro incubation with either control medium and 2 g/ml bendamustine over a time period of 72 h (a, 24 h; b, 48 h; c, 72 h). However, in all cases a significant increase (P Ͻ 0.0001) in the amount of apoptotic cells in bendamustine-treated cells in comparison to the control group could be demonstrated. Ȧ indicates the median percentage of apoptotic cells in each group. n.s., not significant. and 40 g/ml) of bendamustine. After 48 h of incubation the LD50 of bendamustine in the cells of healthy donors could not be determined since most mononuclear cells were still alive. The LD40 for normal cells could be determined with 21.8 g/ml (95% CI 16.1-32.4 g/ml). This is more than eight times higher in comparison to the LD40 of B-CLL cells from pretreated patients (2.5 g/ml; 95% CI 2.1-2.9 g/ml) and five times higher in relation to the LD40 of B-CLL cells from untreated patients (4.3 g/ml; 95% CI 3.8-4.8 g/ml). These results indicate that normal mononuclear cells are much more resistant to bendamustine.
Combination of bendamustine and fludarabine towards CLL cells
Since first clinical trials have been performed to test the combination of bendamustine and fludarabine with regard to their synergistic effect, we investigated this combination in vitro (n = 24). After 24 h all samples, except two, showed a synergistic interaction (determined as an increase of at least 5% of the expected additive rate of the single agent) with a median increase of 150% of the expected apoptosis rate (P Ͻ 0.00005; Figure 5a ). After 48 h in 16/24 samples a synergistic action of the combination of 2 g/ml bendamustine and 0.7 g/ml fludarabine could be evaluated. In these 16 cases the combination led to a median increase of the expected apoptotic rate of 55% (P = 0.01; Figure 5a ). The absence of synergism in six of eight patients after 48 h was caused by the fact that the single apoptotic rate of bendamustine and fludarabine was too high (Ͼ40%) to observe any synergistic action. By using lower concentrations of both drugs, even in these patients synergistic interactions could be detected (data not shown). These data were confirmed by the determination of the combination index (CI) (see Figure 5b ) and corresponding isobologram analysis (see Figure 5c ) after 48 h of incubation. The CI for bendamustine and fludarabine exhibits a strong synergistic action with a value for the combination of 1 g/ml bendamustine/0.35 g/ml fludarabine of 0.74, for 2 g/ml bendamustine/0.7 g/ml fludarabine of 0.26 and for 10 g/ml bendamustine/35 g/ml fludarabine of 0.27. Similar results were obtained with other concentration combinations (n = 8) of bendamustine with fludarabine, confirming the high synergistic interaction (data not shown). After 24 h, the CI method and isobologram analysis failed for the evaluation of synergistic interaction due to insufficient dose response slopes of fludarabine (data not shown).
All patients, except two, who failed to show a synergistic increase in the apoptotic rate, due to the high single apoptosis of bendamustine and fludarabine, were at Binet stage B or C, indicating that this combination was also highly active for patients with diseases in such an advanced stage.
Analysis of the Bcl-2 and Bax protein expression under incubation with 2 g/ml bendamustine
To analyze whether bendamustine initiated apoptosis by either decreased expression of Bcl-2 or increased Bax protein, we measured these levels in in vitro cultured B-CLL cells under the incubation with 2 g/ml bendamustine or in a control medium alone over a period of 48 h (n = 15). Expression levels were determined by FACS analysis with a combination of hamster-anti-human-Bcl-2 MoAb and mouse-anti-humanBax MoAb as described above.
The MFI of Bcl-2 and Bax protein expression varied in B-CLL cells between 6 and 69 for Bcl-2 and 7 and 117 for Bax in control medium over a time period of 72 h. These results were in accordance with previously reported ranges of the MFI of Bcl-2 and Bax protein levels in B-CLL cells. 37, [43] [44] [45] In B-CLL cells incubated with 2 g/ml bendamustine, the MFI for the Bcl-2 and Bax protein level ranged between 0 and 69 for Bcl-2 and 7 and 546 for Bax.
Nevertheless, over a period of 48 h, no changes (Ͼ1 log 10
Figure 5
(a) Flow cytometry analysis of drug-specific apoptotic cells of either 0.7 g/ml fludarabine and 2 g/ml bendamustine alone or in the combination of both drugs in B-CLL cells. The combination of bendamustine with fludarabine led to a median increase of 150% after 24 h in 22/24 cases in the percentage of apoptotic cells (P Ͻ 0.00001). After 48 h, a synergistic interaction of bendamustine in combination with fludarabine could be determined in only 16/24 cases. In these 16 samples, the median apoptotic rate could be increased for 55% (P = 0.01). In six of the remaining eight cases which failed to show synergistic action, the single apoptotic rate of either bendamustine or fludarabine was over 40%, which prevents determination of a synergistic action. concerning mean fluorescence intensity) in the median levels of Bcl-2 and Bax protein expression between bendamustinetreated B-CLL cells and medium cultured cells could be demonstrated (Figure 6a and b) . In six of 15 samples treated with 2 g/ml bendamustine, a tendency for an increase of the Bax protein expression could be detected, resulting in a highly elevated upper quartile range. An additionally performed nonparametric Page test showed no significant alterations for the Bax and Bcl-2 protein expression for bendamustine-treated cells over a time period of 48 h (P = 0.07; P = 0.86). In order to evaluate whether the increased Bax expression in six of 15 patients was related to the previous treatment state or the clinical grading, we performed a multivariance analysis. Here the expression level under incubation with bendamustine was not altered by clinical grading or by previous treatment status.
Analysis of the Bcl-2 and Bax mRNA expression under incubation with 2 g/ml bendamustine
To confirm the results concerning Bcl-2 and Bax protein expression by mRNA-levels, we performed Rnase protection assays n = 4). In these analyses, we hybridized 10 g of total target RNA against 32 P-labeled anti-sense RNA probe for Bcl-2, Bax and the housekeeping genes L32 and GAPDH generated by in vitro transcription from a DNA template set as described above.
No significant difference in the expression of Bcl-2 and Bax mRNA could be detected by autoradiography. Representative images are given in Figure 7a and b. Additionally performed quantification by phosphorimaging and calculation of the relative expression level in relation to the expression of the housekeeping gene L32 and/or GAPDH showed similar expression for Bcl-2 and Bax in all samples (Figure 7c) . In only one sample, a significant change (Ͼ100%) of the Bax expression was detectable (data not shown). Although the Leukemia depicted images are of reduced quality, due to the limited dynamic range of autoradiography, all evaluated data points were in the dynamic range by phosphorimaging, demonstrating the limited significance of autoradiography.
PARP Western blotting of bendamustine-incubated CLL cells
To discriminate between necrosis vs apoptosis and to confirm the FACS data concerning qualification of apoptosis, we performed poly (ADP-ribose) polymerase (PARP) Western blotting after incubating B-CLL cells in medium alone or in 2 g/ml bendamustine. In order to get a positive control for apoptosis, cells from the same patient were cultured in 0.7 g/ml fludarabine for at least 36 h. For cells treated with bendamustine and fludarabine, a cleavage of the 113 kDa PARP protein to the 89 kDa protein was detectable, confirming the results obtained by FACS analysis with the DNA dye 7-AAD ( Figure 8 ).
Discussion
Over the past few decades only little progress in prolonging survival in patients with CLL has been made. 46 For bendamustine, the first promising data from small phase I/II studies showed response rates between 69% and 94% in patients with B-CLL. 23, 24 Up to now, only few in vitro experiments with bendamustine relating to its mechanism of action in CLL are have been carried out. In the present study, the in vitro potential of bendamustine to induce apoptosis in primary B-CLL cells and the underlying mechanisms by which initiated apoptosis is mediated were evaluated for the first time.
We could demonstrate that bendamustine induced apoptosis in a dose-and time-dependent manner in B-CLL lymphocytes in vitro, whereby an elevated dosage seems to be more efficient than a prolonged incubation time. With regard to these results, it could be suggested that the cytotoxic action of bendamustine on non-proliferating B-CLL cells is not a primary result of the implication in replicative DNA. Our results confirm a direct apoptotic mechanism of bendamustine on G0-arrested B-CLL lymphocytes. A possible explanation for the effectiveness of bendamustine in B-CLL may be the apparent requirement of unaffected DNA for continual DNA housekeeping, even in non-proliferating cells.
The comparison of the apoptotic rates and the determination of the LD50 in untreated and pretreated B-CLL patients emphasized the effectiveness of bendamustine in both groups. In a former phase I study testing plasma concentrations after bolus injection of various common dosage schedules (60-130 mg/m 2 ) of bendamustine, a median concentration of 9.8 g/ml (range 4.6 g/ml to 17. 9 g/ml) could be demonstrated (Ribosepharm, personal communication). The median attainable plasma concentration is more than twice the evaluated LD50 of B-CLL cells from pretreated patients in vitro. These findings together contribute to clinical data, indicating a high activity of bendamustine in previously heavily treated patients with B-CLL. 23, 24 In this context MCF7 cells demonstrated lower resistance to bendamustine when compared with other alkylating agents, such as cyclophosphamide, melphalan or BCNU and anthracyclines such as doxorubicin, which probably indicate, that bendamustine has further cytotoxic effects, apart from the alkylating action. 30 These findings were supported by mice model examinations where bone marrow cells incubated with bendamustine, exhibited less chromosomal aberrations (a hallmark of treatment with alkylating agents) in comparison with cells treated with other alkylating agents (Konstantinov, personal communication). In addition, bendamustine induces more long-lasting DNA double strand breaks than other alkylating agents. 30 Such DNA strand breaks could be repaired by a DNA-dependent protein kinase which is composed of a regulatory 80/70 kDa heterodimeric subunit and a catalytic subunit (KU80 and KU70). Previous results indicated that B-CLL cells seem to have a higher ability to repair DNA damage by KU80. KU80-deficient cell lines are markedly sensitive to a group of DNA cross-linking agents, the nitrogen mustards, as compared with their parental cell line. 47, 48 For further studies, it will be of interest whether bendamustine is able to overcome this resistance by the inhibition of the KU80-dependent pathway and the following activation of the poly (ADP-ribose) polymerase.
In contrast to B-CLL cells, the LD40 of normal mononuclear cells from healthy volunteers seems to be higher. This can be caused by a higher resistance of normal T cells in comparison to the small number of circulating B cells in healthy volunteers or by a relatively high specificity of bendamustine to B-CLL cells. Similar results with higher effectiveness of fludarabine or fludarabine in combination with cyclophosphamide towards B-CLL lymphocytes in comparison to healthy T lymphocytes was demonstrated by other groups. 41, 42 In order to induce higher rates of complete remissions, which are associated with improved survival and enables the application of autologous transplantation, we combined bendamustine with fludarabine in vitro. 46, 49 We could demonstrate that this combination acts highly synergistically. After 24 h, the median apoptotic rate was increased more than 150% in comparison with the expected additive sum of apoptotic rates for the individual drugs alone. After 48 h, the synergistic effect of the combination was smaller due to the high apoptotic rates of the single agents (Ͼ40%), making it impossible to measure more than 100% apoptotic cells. With isobologram analysis and CI determinations for eight different combinations of bendamustine and fludarabine, in all cases a high synergistic interaction was evident, underlying the potential of this combination. These results were supported by further in vitro and in vivo studies, demonstrating a high response of B-CLL cells to combinations of alkylating drugs with purine analogs. 42, [50] [51] [52] [53] [54] [55] The underlying mechanism for the synergistic interaction of bendamustine with fludarabine in B-CLL cells is unknown. As mentioned above, bendamustine induces long-lasting DNA double strand breaks, while fludarabine inhibits DNA and RNA synthesis, as well as DNA repair. 30, 56, 57 In this context it can be suggested that the inhibition of DNA interstrand crosslink removal by fludarabine may account for this synergism.
The results represented in this paper could demonstrate that bendamustine induces apoptosis in B-CLL lymphocytes, as well as in lymphocytes derived from healthy donors. This apoptotic pathway seems to be associated with the activation of caspase-3 which is commonly expressed in CLL cells. 13, 58 The activation of caspases results in the cleavage of essential key enzymes, like the PARP molecule which can be used as a marker of activation of the CDE-3/ICE-like proteases and apoptosis. 15, 18, 19, 39, [59] [60] [61] [62] These results complement other observations, which showed caspase-3 activation after bendamustine, flavoperidol, fludarabine, chlorambucil and prednisone treatment in B-CLL cells. 53, [63] [64] [65] The exact mechanism by which bendamustine induces apoptosis in B-CLL cells has not currently been investigated. We therefore determined the Bcl-2 and Bax protein and mRNA expression under incubation with bendamustine. It is known, that Bcl-2 is overexpressed in B-CLL and that an increased Bcl-2/Bax ratio is related to a worse clinical outcome. 9, [66] [67] [68] [69] [70] One potential mechanism for this overexpression may be the elevated transcription following gene hypomethylation. 11 Bax, being a strong promotor for apoptosis, forms heterodimers with Bcl-2 and thus inhibits the antiapoptotic effect of Bcl-2. 71 Whether the initial Bcl-2, Bax or Bcl-2/Bax ratio is correlated to chemotherapy sensitivity in B-CLL patients is still unclear. Concerning this matter, diverse studies delivered no corresponding results. 69, 70, [72] [73] [74] Data about the drug-induced changes of apoptotic regulatory proteins are also still inconsistent. Recently, it was reported that fludarabine could induce Bcl-2 down-regulation in cultured B-CLL cells and that antisense Bcl-2 oligonucleotides results in the induction of apoptosis in B-CLL cells. 14, 37, 70 In our study, the Bcl-2 and Bax expression was determined by RNase protection assay and FACS analysis. Using these methods, we found no significant changes (defined as more than 100% for mRNA expression levels or more than 1 log 10 concerning fluorescence intensity Leukemia for FACS analysis). This is consistent with results reported by Byrd et al 63 for the induction of apoptosis with flavoperidol and Bellosillo et al 42 for apoptosis induction with fludarabine in combination with cyclophosphamide. It is unlikely that a silent up-or down-regulation for Bax or Bcl-2 was masked by other cells, since all patients used for these studies revealed a highly leukemic CLL. In six of 15 samples we could see a tendency for an increase of the Bax protein expression without statistical significance. These results indicated that in a subset of patients, bendamustine was probably able to induce Bax up-regulation. Nevertheless we failed to further narrow this subset of patients by clinical grading or pretreatment status. If higher doses of bendamustine will lead to significant changes in the Bcl-2 and Bax expression in B-CLL cells is unclear. However, quantitative apoptosis occurs under the tested concentrations in CLL cells what makes the necessity of altered expression levels of Bcl-2 and Bax unlikely. Besides the downregulation of Bcl-2, other possible mechanisms for chemotherapy-induced apoptosis might be (1) the caspase-mediated cleavege and inactivation of Bcl-2; or (2) the inactivation of Bcl-2 by phophorylation and subsequent release of cytochrome-c from the mitochondria without changes in the expression level. 18, 75 A further possible pathway for the induction of apoptosis is the activation and stabilization of p53 under incubation with purin analogs and alkylating agents. 76 One of the mechanisms involved in p53 stabilization is the phosphorylation by ataxia telangiectasia mutation (ATM). 77 Very interestingly, p53 and ATM deletions or inactivations has been found in B-CLL and are associated with shorter survival and therapy failure. 76, [78] [79] [80] In conclusion, the present study demonstrates that bendamustine activates programmed cell death in B-CLL cells in vitro at concentrations which are under the commonly used concentrations in clinical schedules. These results support clinical studies, showing that bendamustine is a new effective option for therapy in refractory or relapsed B-CLL. The in vitro results for the combination therapy of bendamustine and fludarabine encouraged the evaluation of this combination in ongoing clinical trials. However the expression of the apoptosis-regulating proteins Bcl-2 and Bax seems to be unchanged under incubation with bendamustine.
